Cambrian Bio

Cambrian BioPharma announced the launch of Amplifier Therapeutics, a biotech focused on developing a clinical-stage AMPK activator.

Metformin is just one of many medications being explored to slow, stop, or even reverse aging.

Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more

Longevity has long been known as a billionaire's sport. A growing community is trying to make it digestible to the drug-making mainstream.

Cambrian Biopharma announced that its latest pipeline company, Isterian Biotech, has emerged from stealth to develop first-in-class medicines to tackle aging.

Oviva Therapeutics just raised $11.5 million to develop drugs based on the work of Mass. General researchers.

Anti-aging researchers have for more than a decade been leading the charge to test the idea of using metformin to extend human healthspan.

Cambrian has added to its age-related disease portfolio via a deal with Novartis for a series of mTOR inhibitors that will be developed by newly launched s...

James Peyer, co-founder and CEO of Cambrian Biopharma, joins CNBC's 'Squawk Box' to discuss what investors need to know about the growing longevity industry.

Achieving sufficient delivery across the blood-brain barrier is a key challenge in the development of drugs to treat central nervous system (CNS) disorders. This is particularly the case for biopharmaceuticals such as monoclonal antibodies and enzyme repl